Table 1.

Efficacy Through W100 (NRI)

Data are %GUS Q4WGUS Q8WPBO→GUS Q4W
W24W52W100W24W52W100W24W52W100
Analysis set, n245248246
 ACR 50334656324855144148
 ACR 7013263519283641830
BL HAQ-DI ≥0.35, n228228236
Improvement ≥0.35a565963505864314856
BL ≥3% BSA psoriasis + IGA ≥2, n184176183
 IGA0/1696362715855196367
 PASI75788783798682238380
PASI90617774697470107277
PASI10045585945535335261
  • BL, Baseline; BSA, Body surface area; HAQ-DI, Health assessment questionnaire disability index; IGA, Investigator global assessment; NRI, nonresponder imputation; PASI, Psoriasis area and severity index. a≥0.35 improvement among pts with HAQ-DI ≥0.35 at BL.